The success of Ozempic and Wegovy has turned Novo Nordisk into Europe’s biggest company. But Eli Lilly’s newest version of GLP-1 drug, Zepbound, could take a big bite out of the market. Amid rising obesity rates and increasing demand for weight-loss solutions, valuations for both pharmaceutical giants are soaring.
Learn more: https://www.bloomberg.com/news/features/2024-01-26/zepbound-how-eli-lilly-s-lucky-break-fueled-a-600b-weight-loss-empire?srnd=bigtake
#Ozempic #Wegovy #Zepbound
--------
Like this video? Subscribe: http://www.youtube.com/Bloomberg?sub_confirmation=1
Become a Quicktake Member for exclusive perks: http://www.youtube.com/bloomberg/join
Bloomberg Originals offers bold takes for curious minds on today’s biggest topics. Hosted by experts covering stories you haven’t seen and viewpoints you haven’t heard, you’ll discover cinematic, data-led shows that investigate the intersection of business and culture. Exploring every angle of climate change, technology, finance, sports and beyond, Bloomberg Originals is business as you’ve never seen it.
Subscribe for business news, but not as you've known it: exclusive interviews, fascinating profiles, data-driven analysis, and the latest in tech innovation from around the world.
Visit our partner channel Bloomberg Quicktake for global news and insight in an instant.